Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EYP-651
- Development stage
- Phase 1
- Lead developer
- ENYO Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
EYP-651 is an orally administered, small molecule drug under development by Enyo Pharma for the treatment of chronic kidney disease (CKD), non-alcoholic steatohepatitis (NASH, also referred to as metabolic dysfunction-associated steatohepatitis or MASH) in patients with renal impairment, and diabetic kidney disease. It acts as a highly specific agonist of the farnesoid X receptor (FXR), a bile acid nuclear receptor involved in regulating bile acid homeostasis, lipid metabolism, inflammation, and fibrosis. By activating FXR and modulating mitochondrial NEET proteins, EYP-651 is designed to exert anti-inflammatory and fibrolytic effects that may slow or reverse progression of kidney diseases characterized by inflammation and fibrosis. The drug is considered a "fast follower" to vonafexor (EYP001), another FXR agonist from Enyo Pharma[1][2][3][4][5][6][8].
- Other names
- EYP 651EYP651EYP-651
02
Targets
FXR (Farnesoid x-activated receptor)CISD1 (CDGSH iron-sulfur domain-containing protein 1)
Beyond the preview
Go deeper on EYP-651.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EYP-651.